Valuation dashboard for Cytokinetics, Incorporated (CYTK) with P/E N/A, P/B -52.77, EV/EBITDA -11.34 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Analysis Summary
Cytokinetics, Incorporated reported revenue of $88.0M in the most recent fiscal year, growing at a 5-year CAGR of 9.5%.
Trailing-twelve-month margins: gross margin 85.0%, operating margin -9.9%, net margin -12.6%.
At the current price of $69.90, CYTK has negative trailing earnings (P/E not meaningful) and an ROE of 119.00%. Market capitalisation stands at $8.7B.
Balance sheet quality for CYTK: current ratio of 4.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -52.77 |
| EV / EBITDA | -11.34 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-62.85 |
| vs Current Price | -189.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CYTK | Cytokinetics, Incorporated | $9.1B | 119.0% | ||
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| AXSM | Axsome Therapeutics, Inc. | $10.9B | |||
| ABVX | Abivax S.A. | $7.5B | 15.11 | -73.9% | |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 30.18 | 86.81 | |
| CRSP | CRISPR Therapeutics AG | $5.0B | 2.86 | ||
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
Price
| Price | $69.90 |
| Market Cap | $8.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 119.00% |
| Return on Invested Capital | -47.74% |
| Return on Assets | -55.10% |
| Gross Margin | 84.97% |
| Operating Margin | -992.98% |
| Net Margin | -1259.87% |
Related companies: ABVX · AXSM · CORT · CRSP · HALO · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of CYTK: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks